Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


"I knew as soon as I heard about [ALTUVIIIO] that it would be the first Factor VIII replacement therapy with the possibility of once-weekly dosing for me, and that higher levels throughout the week would be possible.”
 

Taking an active role in my treatment 

When I was younger, information and treatment options were limited. Now, we have resources and options. I stay informed about new and emerging therapies and discuss them with my doctor, but for those who do not have the years of lived experience that I have and are not regularly following new treatments, HCPs should be updating their patients about these new options at their annual or semiannual visits.
 

Considering the switch

I know that switching treatments can be a hassle, and that it may feel easier to stay with what you have. But I am always on the lookout for a therapy that will give me the results that I want: striving for zero bleeds, easy treatment schedule, easy transport when traveling, coverage throughout the week, and the simplicity and convenience of using one treatment in the event of emergencies. I’ve tried 7 different treatments over my lifetime, switching as new ones have been developed.
 

Making the switch

It was easy for me to make the switch, and I’m glad I did. Once my doctor prescribed ALTUVIIIO, the 30-day trial gave me the opportunity to determine whether ALTUVIIIO was right for me.*
 

Expectations vs experience

Being on top of, and consistent with, my treatment and health is very important to me, especially at my age. I’m at a place where if I don’t stay active, then I’m not going to be active. So, I try to get to the gym regularly, and that helps me have the mobility I need when I’m traveling to places like Edinburgh or when I’m hiking or skiing. I couldn’t do any of this if I didn’t take my health and treatment seriously.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Chris R is a promotional speaker compensated by Sanofi and received free product through Sanofi's Support Program.

*Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Discover More Patient Experiences

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2508205-v1.0-11/2025 Last Updated: November 2025